HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
Devra J. Olson(University of Washington Bothell), Anita Kulukian(University of Washington Bothell)
Cited by 18
Related Papers
No related papers found
Powered by citation graph analysis